Noroxymorphone

Add links
Source: Wikipedia, the free encyclopedia.
Noroxymorphone
Clinical data
Dependence
liability		High (same oxymorphone)
Routes of
administration		intravenous, intramusucular, subcutaneous, oral, rectal, intranasal
Legal status
Legal status
Identifiers
  • 7,8-Dihydro-14-hydroxynormorphinone
JSmol)
  • Oc1ccc2C[C@H]3NCC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O
  • InChI=1S/C16H17NO4/c18-9-2-1-8-7-11-16(20)4-3-10(19)14-15(16,5-6-17-11)12(8)13(9)21-14/h1-2,11,14,17-18,20H,3-7H2/t11-,14+,15+,16-/m1/s1
  • Key:HLMSIZPQBSYUNL-IPOQPSJVSA-N

Noroxymorphone is an

blood-brain-barrier into the central nervous system, and for this reason, has only minimal analgesic activity.[2][3][1]

In the United States, noroxymorphone is controlled as a Schedule II Narcotic controlled substance with an ACSCN of 9637 and in 2014 the DEA set annual aggregate manufacturing quotas of 17 500 kilogrammes for conversion and 1262.5 kg for sale.[4] In other countries, it may be similarly controlled, controlled at a lower level, or regulated in another way.

See also

References

  1. ^
    S2CID 16524280
    .
  2. ISBN 978-0-12-800677-1
    .
  3. ISBN 978-0-19-530055-0
    .
  4. ^ Drug Enforcement Administration (August 25, 2014). "Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014". Federal Register. Vol. 79, no. 164. pp. 50700–50704. Archived from the original on March 4, 2016. Retrieved February 27, 2016.


Stub icon

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Noroxymorphone&oldid=1204978420"